A recent Federal Circuit decision involving Pfizer’s COVID-19 treatment Paxlovid highlights an important patent lesson: a provisional patent application can be valuable, but it only protects what it actually describes.
What the Enanta v. Pfizer Decision Actually Decided
The case involved a patent directed to coronavirus-related antiviral technology. Enanta Pharmaceuticals tried to rely on an earlier provisional patent application to support later patent claims asserted against Pfizer. But the Federal Circuit agreed that the provisional application did not adequately describe the version of the invention Enanta later needed.
That priority issue was critical. Because Enanta could not rely on the earlier provisional filing date, Pfizer’s own earlier public disclosure became prior art against Enanta’s patent. The result was that Enanta’s patent claims were found invalid.
The takeaway is not that provisional patent applications are ineffective. They can be useful, especially when an inventor or business wants to preserve an early filing date while continuing to develop the invention. But a provisional application should not be treated as a rough placeholder that can be fixed later. If important details are missing, the applicant may not be able to rely on the provisional filing date when those details become important in the later non-provisional application.
What Makes a Provisional Application Strong?
A strong provisional patent application is not just a quick summary of an idea. It should describe the invention with enough detail to support the patent claims that may be filed later. That usually means including:
- A detailed written description of the invention. The application should explain what the invention is, how it works, and what makes it different from existing products or methods.
- Figures that show the important features. Drawings, diagrams, flowcharts, screenshots, or system layouts can help show the structure and operation of the invention. Even simple figures can be valuable if they clearly identify the important components.
- Specific details, not just broad concepts. Instead of saying that the invention “improves efficiency” or “uses software,” the application should explain the components, steps, relationships, and operation that create the improvement.
- Multiple versions or variations of the invention. A good provisional often describes alternative structures, materials, configurations, steps, or use cases. This can help preserve flexibility when claims are drafted later.
- Enough disclosure to support future claims. The provisional should be written with an eye toward what the applicant may eventually want to claim. If an important feature is missing from the provisional, the applicant may not be able to rely on the provisional filing date for that feature later.
- Examples of how the invention may be used. Practical examples can help show how the invention works in the real world and why the disclosed features matter.
What This Means If You Are Filing a Provisional Patent Application
The goal is not perfection. A provisional application does not need to include formal claims or every detail that may appear in a later non-provisional application. But it should provide a real, meaningful disclosure of the invention. The stronger the description, figures, and examples are at the provisional stage, the more useful the provisional application may be later.
Jones Intellectual Property works with inventors and businesses to prepare provisional patent applications that are detailed, strategic, and aligned with future patent goals. If you are thinking about filing a provisional application, it is worth taking the time to make sure the application describes the invention clearly, includes useful figures, and supports the protection you may need later.
FAQs
Q: What did the Federal Circuit decide in Enanta v. Pfizer?
A: On June 23, 2026, the Federal Circuit affirmed that all claims of Enanta Pharmaceuticals’ U.S. Patent 11,358,953 are invalid. The court held that Enanta’s provisional application failed to provide adequate written description support under 35 U.S.C. § 112 for a key chemical substituent. The provisional disclosed alkyl groups containing two to twelve carbon atoms, but the issued patent claimed a one-carbon alkyl group, the form found in nirmatrelvir, Pfizer’s active ingredient in Paxlovid. Because the provisional did not disclose the one-carbon version, the patent could not claim the provisional’s July 2020 priority date. Pfizer’s April 2021 public disclosure of nirmatrelvir then became prior art that anticipated Enanta’s claims.
Q: What is the written description requirement for a provisional patent application?
A: Under 35 U.S.C. § 112, a patent can claim the benefit of an earlier provisional filing date only if the provisional adequately describes the invention claimed in the later patent. The Federal Circuit in Enanta v. Pfizer explained that this requirement is met only when the provisional shows the inventor was “in possession of the claimed invention” at the time of filing. A provisional that omits a key feature of the invention, even by what the applicant later argues was a typo, may not satisfy this standard.
Q: What happens if my provisional application doesn’t fully describe my invention?
A: If the provisional does not adequately support the claimed invention, the issued patent cannot rely on the provisional’s earlier filing date. As Enanta v. Pfizer illustrates, if a competitor publicly discloses a similar invention between the provisional filing date and the non-provisional filing date, that disclosure can become prior art that invalidates the patent entirely. This is why the article’s core advice holds: a provisional should not be treated as a rough placeholder that can be filled in later.
Q: Can a typo in a provisional patent application be fixed in the non-provisional?
A: Not reliably. In Enanta v. Pfizer, Enanta argued that “C2” in the provisional was a typographical error that should have read “C1.” The Federal Circuit rejected this, finding the alleged error was “subject to reasonable debate” and that nothing in the specific substituent disclosure indicated the inventors possessed a one-carbon group. The court quoted its own standard: “We respect applicants’ statements in their specification that they invented what was specifically disclosed in the ‘048 provisional, but similarly we conclude that they did not invent what they did not disclose.” Courts may only correct an issued patent where the correction is not subject to reasonable debate.
